GLP1 Analogues and the Risk of Osteoarthritis

NCT07360457 | Not Yet Recruiting

• 1 other identifier: GLP1
• Study Type: observational
• Target: 390
• Locations: 0 countries
• Sites: N/A

Brief Summary

Assessing the effects of GLP1 RA Vs SGLT2 Inhibitors vs. Standard of care in joint pain, physical function, stiffness, and improving Quality of Life for patients with type 2 diabetes.

Conditions

Osteoarthritis

Keywords

GLP-1

Outcome Measures

Primary Outcomes (1)

• WOMAC score

  A validated, self-administered questionnaire used to assess pain, stiffness, and physical function

  at Day 1

Secondary Outcomes (1)

• VAS pain score

  at Day 1

Study Arms (3)

SGLT2 Group

T2DM patients receiving SGLT2 inhibitors for at least 1 year added to their standard of care

Drug: SGLT2 inhibitor

GLP1 Group

T2DM patients receiving GLP1 analogues for at least 1 year added to their standard of care

Drug: GLP-1 analog

Control group

T2DM patients receiving only standard of care

Drug: Antidiabetic

Interventions

GLP-1 analog DRUG

glucagon like peptide analogues

Also known as: GLP1 receptor agonist

GLP1 Group

SGLT2 inhibitor DRUG

sodium glucose transporter-2 inhibitors

Also known as: gliflozin

SGLT2 Group

Antidiabetic DRUG

Standard of care

Also known as: Control

Control group

Eligibility Criteria

• Age: 50 Years+
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)
• Sampling Method: Non-Probability Sample

Study Population

130 T2DM patients will be admitted in each group Group 1 : T2DM patients receiving SGLT2 inhibitors for at least 1 year added to their standard of care Group 2: T2DM patients receiving GLP1 analogues for at least 1 year added to their standard of care Group 3: T2DM patients receiving only standard of care

You may qualify if:

• Adults aged above 50 years old with a previous diagnosis of T2DM according to ADA 2025, who have been on either SGLT2 inhibitors or GLP-1 analogs for at least one year.

You may not qualify if:

• individuals with Type 1 Diabetes Mellitus
• non-diabetic individuals
• those taking prandial insulin
• patients with arthritis without osteoarthritis,
• those taking other medications contraindicated with study medications,
• pregnant or breastfeeding females
• those allergic to active ingredients,
• those using corticosteroids, Autoimmune disease patients or patients receiving immunotherapies, monoclonal antibody targeting TNF-α or IL-6.

Sponsors & Collaborators

• Beni-Suef University: lead

MeSH Terms

Conditions

Osteoarthritis

Interventions

Sodium-Glucose Transporter 2 Inhibitors; Hypoglycemic Agents

Condition Hierarchy (Ancestors)

Arthritis; Joint Diseases; Musculoskeletal Diseases; Rheumatic Diseases

Intervention Hierarchy (Ancestors)

Molecular Mechanisms of Pharmacological Action; Pharmacologic Actions; Chemical Actions and Uses; Physiological Effects of Drugs

Study Officials

• Asmaa Elsayed

  Sohag University

  PRINCIPAL INVESTIGATOR

Central Study Contacts

Asmaa A Elsayed

CONTACT

01095727201; asmaa.abdelfattah@pharm.sohag.edu.eg

Study Design

• Study Type: observational
• Observational Model: OTHER
• Time Perspective: CROSS SECTIONAL
• Sponsor Type: OTHER
• Responsible Party: PRINCIPAL INVESTIGATOR
• PI Title: Lecturer of clinical pharmacy

Study Record Dates

• First Submitted: January 8, 2026
• First Posted: January 22, 2026
• Study Start: February 1, 2026
• Primary Completion (Estimated): December 1, 2026
• Study Completion (Estimated): March 1, 2027
• Last Updated: January 22, 2026

Record last verified: 2026-01

Data Sharing

• IPD Sharing: Will not share